1.40
-0.01 (-0.71%)
| Penutupan Terdahulu | 1.41 |
| Buka | 1.41 |
| Jumlah Dagangan | 2,051,166 |
| Purata Dagangan (3B) | 3,147,770 |
| Modal Pasaran | 375,030,912 |
| Harga / Pendapatan (P/E Ke hadapan) | 28.74 |
| Harga / Jualan (P/S) | 1.18 |
| Harga / Buku (P/B) | 10.14 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Keuntungan | -24.51% |
| Margin Operasi (TTM) | 23.85% |
| EPS Cair (TTM) | -0.210 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 75.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 795.72% |
| Nisbah Semasa (MRQ) | 2.23 |
| Aliran Tunai Operasi (OCF TTM) | -34.81 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 12.96 M |
| Pulangan Atas Aset (ROA TTM) | -4.26% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Menaik | |
| Stok | Akebia Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.10 |
|
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 3.59% |
| % Dimiliki oleh Institusi | 38.96% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ADAMS ADRIAN | 1.02 | - | 35,700 | 36,414 |
| FRIESON RON | 1.02 | - | 35,700 | 36,414 |
| ROGERS MICHAEL W | 1.02 | - | 35,700 | 36,414 |
| SMITH CYNTHIA | 1.02 | - | 35,700 | 36,414 |
| WOLF MYLES | 1.02 | - | 35,700 | 36,414 |
| ZUMWALT LEANNE M | 1.02 | - | 35,700 | 36,414 |
| Jumlah Keseluruhan Kuantiti Bersih | 214,200 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 218,484 | |||
| Purata Pembelian Keseluruhan ($) | 1.02 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| ADAMS ADRIAN | Pengarah | 17 Jun 2026 | Diperolehi (+) | 35,700 | 1.02 | 36,414 |
| ZUMWALT LEANNE M | Pengarah | 17 Jun 2026 | Diperolehi (+) | 35,700 | 1.02 | 36,414 |
| FRIESON RON | Pengarah | 17 Jun 2026 | Diperolehi (+) | 35,700 | 1.02 | 36,414 |
| ROGERS MICHAEL W | Pengarah | 17 Jun 2026 | Diperolehi (+) | 35,700 | 1.02 | 36,414 |
| SMITH CYNTHIA | Pengarah | 17 Jun 2026 | Diperolehi (+) | 35,700 | 1.02 | 36,414 |
| WOLF MYLES | Pengarah | 17 Jun 2026 | Diperolehi (+) | 35,700 | 1.02 | 36,414 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |